Your browser doesn't support javascript.
loading
Predictive factors for response to lamivudine in chronic hepatitis B
Silva, Luiz Caetano da; Fonseca, Luís Edmundo Pinto da; Carrilho, Flair José; Alves, Venâncio Avancini Ferreira; Sitnik, Roberta; Pinho, João Renato Rebello.
Afiliação
  • Silva, Luiz Caetano da; Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Departamento de Gastroenterologia. Säo Paulo. BR
  • Fonseca, Luís Edmundo Pinto da; Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Departamento de Gastroenterologia. Säo Paulo. BR
  • Carrilho, Flair José; Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Departamento de Gastroenterologia. Säo Paulo. BR
  • Alves, Venâncio Avancini Ferreira; Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Departamento de Patologia. Säo Paulo. BR
  • Sitnik, Roberta; Laboratório Bioquímico Jardim Paulista. Säo Paulo. BR
  • Pinho, João Renato Rebello; Instituto Adolfo Lutz. Laboratório de Biologia Molecular. Säo Paulo. BR
Rev. Inst. Med. Trop. Säo Paulo ; 42(4): 189-96, July-Aug. 2000. tab, graf
Article em En | LILACS | ID: lil-266051
Biblioteca responsável: BR1.1
ABSTRACT

BACKGROUND:

Lamivudine has been shown to be an efficient drug for chronic hepatitis B (CHB) treatment.

AIM:

To investigate predictive factors of response, using a quantitative method with high sensitivity.

METHODS:

We carried out a prospective trial of lamivudine in 35 patients with CHB and evidence for viral replication, regardless to their HBeAg status. Lamivudine was given for 12 months at 300 mg daily and 150 mg thereafter. Response was considered when DNA was undetectable by PCR after 6 months of treatment. Viral replication was monitored by end-point dilution PCR. Mutation associated with resistance to lamivudine was detected by DNA sequencing in non-responder patients.

RESULTS:

Response was observed in 23/35 patients (65.7 per cent) but only in 5/15 (33.3 per cent) HBeAg positive patients. Only three pre-treatment variables were associated to low response HBeAg (p = 0.006), high viral load (DNA-VHB > 3 x 10(6) copies/ml) (p = 0.004) and liver HBcAg (p = 0.0028). YMDD mutations were detected in 7/11 non-responder patients.

CONCLUSIONS:

HBeAg positive patients with high viral load show a high risk for developing drug resistance. On the other hand, HBeAg negative patients show a good response to lamivudine even with high viremia.
Assuntos
Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Lamivudina / Fármacos Anti-HIV / Hepatite B Crônica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Rev. Inst. Med. Trop. Säo Paulo Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2000 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil
Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Lamivudina / Fármacos Anti-HIV / Hepatite B Crônica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Rev. Inst. Med. Trop. Säo Paulo Assunto da revista: MEDICINA TROPICAL Ano de publicação: 2000 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil